Navigation Links
OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Date:10/13/2008

ncer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration. OGX-011 is being evaluated in five Phase 2 clinical trials, each of which has completed patient enrollment. Interim study results have previously been presented for each of the five clinical trials.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning agreements with the FDA regarding endpoints and clinical trial design and anticipated clinical and other product development activities and timing of these activities. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumpti
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
2. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
3. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
4. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. OncoGenex increases economic interest in lead cancer drug OGX-011
7. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
10. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
11. Realtime Achieves ISO 13485:2003 Certification Targeting BioTech Quality Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & ... stem cell technology start-up company Asymmetrex to share the first report on ... a new biomarker for counting adult tissue stem cells. , With a name like ...
(Date:8/25/2015)... Aug. 25, 2015 Human Longevity, Inc. (HLI), the ... has joined the company as Chief Operating Officer. Winham, ... operations and technical experience, will report directly to HLI,s CEO, ... this new role as COO, Winham will be responsible for ... well as all facility operations. HLI currently has three locations ...
(Date:8/25/2015)... Aug. 25, 2015 Doximity, the leading ... physicians, today launched its second annual Residency ... the next generation of doctors research and compare ... percent of all senior medical students used Doximity ... as new physicians. The new Residency Navigator brings ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2Doximity Releases 2015-2016 Residency Navigator 2Doximity Releases 2015-2016 Residency Navigator 3
... Inc. (Amex:,ADL), headquartered in Tustin, California, with ... its wholly owned subsidiary Jade,Pharmaceutical Inc., is ... development, manufacture and marketing of proprietary pharmaceutical,and ... detailed report on the,Company, its prospects in ...
... Orifice Surgery, AUSTIN, Texas, Oct. 8 ... devices for minimally invasive,surgical procedures conducted through natural ... Series A financing from PTV Sciences, H.I.G.,Ventures, and ... to complete product development and conduct human clinical ...
... Preliminary results from a,clinical study comparing INVEGA(TM) (paliperidone) ... in patients with,recent, acute exacerbation of schizophrenia will ... the 20th Annual U.S. Psychiatric and Mental Health,Congress, ... FL. The poster, entitled "A Comparative Analysis ...
Cached Biology Technology:ValueRich Report on AMDL/China Available on Web Site 2Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing. 2Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing. 3Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 2Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 3Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress 4
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... system, every protein made in the cell has a specific ... proteins to their appropriate target. Researchers at Boston University ... images of these channels as they open to allow proteins ... made. These findings are published as a Letter in ...
... apps, cameras, and mobile internet to navigate strange cities in ... in line, and upload their videos directly to social media ... high-tech savvy can save a well-loved device from dying when ... same basic ailment that plagues solar power plants and wind ...
... A drug currently on the market to treat leukemia reversed ... findings by medical researchers with the University of Alberta. ... team,s discovery in the peer-reviewed journal, PLOS ONE . ... can also play an important role in the development of ...
Cached Biology News:Researchers capture images of open channel that moves proteins across cell membranes 2Futuristic copper foam batteries get more bang for the buck 2Futuristic copper foam batteries get more bang for the buck 3UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3